Peer-reviewed myeloma studies that include fenbendazole
-
Targeting the microtubular network as a new antimyeloma strategy (2011) – Molecular Cancer Therapeutics
-
What it is: In-vitro (MM cell lines; also includes stromal co-culture work) and in-vivo xenograft work focused on benzimidazoles/microtubule disruption; the paper includes fenbendazole among the benzimidazoles tested in MM cell experiments.
-
Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents (2010) – Leukemia Research
-
What it is: A screening study in MM context (drug discovery / repurposing-style screen). This is part of the same research line that later published the 2011 Mol Cancer Ther paper above; it’s one of the key “upstream” studies leading into the benzimidazole findings.
Conference abstract (still a “study,” but not a full peer-reviewed paper)
-
Nocodazole Induces Myeloma Cell Death… (ASH meeting abstract; 2008) – Blood (abstract)
-
What it is: A myeloma-focused report (conference abstract) noting identification of benzimidazoles including fenbendazole in the MM screening/analysis context.
-
Link: https://ashpublications.org/blood/article/112/11/3673/61394/Nocodazole-Induces-Myeloma-Cell-Death-by
What I did not find (important)
-
No human clinical trials of fenbendazole specifically in multiple myeloma in the indexed biomedical literature surfaced in these searches. (There are benzimidazole relatives like mebendazole and flubendazole with myeloma preclinical data, but that’s not fenbendazole.)
If you want, I can also provide a separate section listing the closest “adjacent” evidence(mebendazole/flubendazole/albendazole in MM) with PubMed links—useful for context, but distinct from “fenbendazole + myeloma” specifically.